ASTRAZENECA ONCOLOGY EDUCATION. Invitation Nordic - Baltic Masterclass. BRCA tumor testing

Relaterede dokumenter
Hvad er en biobank? Hvad skal vi forvente af regionernes biobanker? Hvorfor har og får de en rolle?

The concept of neoadjuvant chemotherapy in breast cancer.

Living with Statins. Final Symposium. University of Copenhagen

Agenda. The need to embrace our complex health care system and learning to do so. Christian von Plessen Contributors to healthcare services in Denmark

Danish Language Course for International University Students Copenhagen, 12 July 1 August Application form

BANGKOK FASE 2 - VALGFAG INFORMATION, VEJLEDNING OG DOKUMENTER

Danish Language Course for Foreign University Students Copenhagen, 13 July 2 August 2016 Advanced, medium and beginner s level.

PATIENTINDDRAGELSE PATIENTOPLEVELSER OG PATIENTSIKKERHED

To the reader: Information regarding this document

Godkender modtagelse af donation. Kontoansvarlig hospitalsperson. Centerdirektør. Centerdirektør Johannes Jakobsen. Johannes Jakobsen.

May 21 Auditorium A Neoadjuvant chemotherapy in breast cancer and prophylactic mastectomy

Engelsk. Niveau C. De Merkantile Erhvervsuddannelser September Casebaseret eksamen. og

Healthcare Apps. OUH Odense University Hospital & Svendborg Hospital. Kiel, Germany, November /12/13

Main Sponsor 2015 : Roche a/s

BRCA mutationer og brystkræft

Engelsk. Niveau D. De Merkantile Erhvervsuddannelser September Casebaseret eksamen. og

Are you hiring Newcomers?

Agenda Subject Time Status Annex Comments

Trolling Master Bornholm 2015

Main Sponsor: Roche A/S

Strategic Capital ApS has requested Danionics A/S to make the following announcement prior to the annual general meeting on 23 April 2013:

Nordisk Tænketank for Velfærdsteknologi

En begynderguide til Etisk Nævn for Lægemiddelindustrien

Udbud på engelsk i UCL. Skabelon til beskrivelse

Page 2: Danish. Page 4: English

Brystkræftscreening og overdiagnostik hvordan forstår vi stigningen i incidens?

Business Opening. Very formal, recipient has a special title that must be used in place of their name

Business Opening. Very formal, recipient has a special title that must be used in place of their name

NEXT NYHEDSBREV #5 2016

Masters Thesis - registration form Kandidatafhandling registreringsformular

Application form for access to data and biological samples Ref. no

Det skal du vide, når du som sundhedsperson samarbejder med en virksomhed

Medinddragelse af patienter i forskningsprocessen. Hanne Konradsen Lektor, Karolinska Institutet Stockholm

DK - Quick Text Translation. HEYYER Net Promoter System Magento extension

Branchegruppen for Life Sciences

Leverandørdialog. R2 Group A/S. R2 Group A/S. Nøglen til at være REACH parat V. Jan Skov Nørby

A Strategic Partnership between Aarhus University, Nykredit & PwC. - Focusing on Small and Medium-sized Enterprises

FREMTIDENS KOMPETENCER OG UDDANNELSE INDENFOR INTENSIV SYGEPLEJEN

Must I be a registered company in Denmark? That is not required. Both Danish and foreign companies can trade at Gaspoint Nordic.

Trolling Master Bornholm 2015

Vores mange brugere på musskema.dk er rigtig gode til at komme med kvalificerede ønsker og behov.

Meget formel, modtager har en meget speciel titel som skal bruges i stedet for deres navne

Meget formel, modtager har en meget speciel titel som skal bruges i stedet for deres navne

VidenForum Fokus på viden Viden i fokus

X M Y. What is mediation? Mediation analysis an introduction. Definition

Biobankernes rolle i personlig medicin

Ulovlige posts eller likes på de sociale medier. Martin Dræbye Gantzhorn og Christian Vinding Thomsen

Eksempel på eksamensspørgsmål til caseeksamen

STUDIEOPHOLD I BANGKOK FASE 1 - ANSØGNING - VEJLEDNING OG PROCEDURER

HANDLEPLAN FOR ØGET ÅBENHED I SAMARBEJDET MELLEM

1 s01 - Jeg har generelt været tilfreds med praktikopholdet

The EAL Jobportal. How to get started

Feedback Informed Treatment

GUIDE TIL BREVSKRIVNING

FAKTAARK OM ÆGGESTOKKRÆFT. Hvad er æggestokkræft?

Mission and Vision. ISPE Nordic PAT COP Marts Jesper Wagner, AN GROUP A/S, Mejeribakken 8, 3540 Lynge, Denmark

Metoder i vaskulær biologi

Effekt af interventionsprogrammet Bedre hverdag med kræft til personer med fremskreden kræft, der lever i eget hjem


Modtageklasser i Tønder Kommune

Knee-extension strength or leg-press power after fast-track total knee arthroplasty: Which is better related to performance-based and selfreported

Application form - au pair (please use block capial letters when filling in the form)

Transkript:

ASTRAZENECA ONCOLOGY EDUCATION Invitation Nordic - Baltic Masterclass BRCA tumor testing February, 28 th 2017

In co-operation with: Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen, AstraZeneca arranges a Nordic Baltic Master Class Course Summary: The course will focus on BRCA tumor testing in ovarian and breast cancer Topics covered will focus on BRCA1 & BRCA2 mutations Which patient s should we test? How to test BRCA? Who is going to prescribe the BRCA test? How should the genetic counselling process look like? What could become the future (somatic & germline testing)? Date and time: Tuesday the 28th February 2017 at 9:30 to 16:30 Meeting place: Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen V https://www.scandichotels.com/hotels/denmark/copenhagen/scandic-copenhagen Participants: Healthcare professionals working within oncology, pathology, genetics and biochemistry Signing up for the course: Before 15th February via email to mette.sorensen@astrazeneca.com Please state country, workplace, your name and telephone number. Numbers of seats limited. Final registration will be confirmed by AstraZeneca AstraZeneca cannot reimburse your travel costs

Program Tuesday the 28 th February 2017 9:30-10:00 Coffee Welcome and introduction Why focus on BRCA1 and BRCA2 - How far are we? 10:00-10:15 Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen Hereditary breast and ovarian cancer - Consequences for the patient and their family 10:15-10:45 Anne-Marie Gerdes, Professor, Ph.d., Head of Genetic Clinic, Review of Danish guidelines in BRCA mutated Patients in breast cancer 10:45-11:15 Bent Ejlertsen, Prof. Ph.d., Head of DBCG, Dept. Of Oncology, Norwegian germline BRCA testing up-front at diagnosis on patients with breast cancer 11:15-11:45 Lovise Mæhle, MD, Ph.d. Head of Heriditary cancer unit, Oslo University Hospital Lunch 11:45 12:45 Review of Danish guidelines in BRCA mutated Patients in breast cancer 12:45-13:15 Claus Høgdall, Professor Dr. Sc., Gynaecologic Clinic, Why do we need tumor testing in ovarian cancer and who should be tested 13.15-13.45 Mansoor Mirza, Chief Oncologist, Dept. of Oncology, KIU Women with reproductive cancers Patient Association perspectives 13:45-14:15 Birthe Lemley, President of KIU (Kræft I Underlivet) Coffee 14:15 14:30

How do we test in blood? What are the technical issues? 14:30-15:00 Mads Thomassen, Associate Professor, Molecular biologist, Ph.d., Human Genetics, Department of Clinical Research, Odense University Hospital How do we test in tissue? What are the technical issues? 15:00-15:30 Tim Svenstrup Poulsen, Molecular Biologist, Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen Classification of variants and implications for testing tumor tissue for germline mutations 15:30 16:00 Thomas Hansen Head Biochemist, Ph.d., Center of Genomic Medicine, Wrap-up and future demands for testing 16:00 16:30 Estrid Høgdall, Professor,Dr.,Sc.,Ph.d., Head of Molecular Unit, Herlev Hospital

Yours sincerely Estrid Høgdall Professor, Dr., Sc., Ph.d. Head of Molecular Unit Herlev Hospital Per Barfod Nordic Diagnostic Manager Mette Sørensen Strategic Account Manager Ulla Jensen National Oncology Lead DK Det er med AstraZenecas invitation og den relaterede økonomiske støtte ikke intentionen at fremkalde eller begunstige ordination af AstraZeneca lægemidler eller enhver anden uretmæssig handling som begunstiger AstraZeneca. Hvis du deltager i foranstaltninger eller afgørelser, der berører et AstraZeneca produkt eller brug (f.eks. registrering af et lægemiddel eller tilskud, udbud) inden for en rimelig frist efter at være blevet valgt som deltager / delegeret, bør du overveje ikke at deltage i disse foranstaltninger eller afgørelser, for at undgå enhver opfattelse af utilbørlig indflydelse. Iflg. Reklamebekendtgørelsen må kun sundhedspersoner deltage i AstraZenecas efteruddannelsesarrangementer. Ved sundhedspersoner forstås læger, tandlæger, dyrlæger, farmaceuter, sygeplejersker, veterinærsygeplejersker, farmakonomer, jordemødre, bioanalytikere, kliniske diætister, radiografer, social- og sundhedsassistenter og studerende inden for disse fag. Når du tilmelder dig dette møde, indsamler AstraZeneca dine personoplysninger (fx navn, e-mail). Formålet med indsamlingen er at administrere og bekræfte din deltagelse i mødet. AstraZeneca opbevarer dine oplysninger i en periode på 6 måneder fra den dato, hvor mødet finder sted. Ved at kontakte os skriftligt, kan du anmode om kopi af de oplysninger, som AstraZeneca har om dig, og/eller anmode om korrektion af dine oplysninger. Ved at sende os dine oplysninger, accepterer du behandlingen af dine personoplysninger som beskrevet. Arrangementet vil blive anmeldt til Etisk Nævn for Lægemiddelindustrien (ENLI), inden arrangementets afholdelse, og arrangementet er i sin eksisterende form og indhold forhåndsgodkendt af ENLI. ATLAS APPROVAL ID Number 1025907,011,, Arne Jacobsens Allé 13, DK-2300 Copenhagen S. www.connectinhealth.dk